SCHEMBL7345541

SCHEMBL7345541

CC(C)(C)OC(=O)CN1CCC(/C=C/c2ccc3c(c2)c(S(C)(=O)=O)nn3C2CCN(CC(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 7/20 0.37
▸ GPR119 Q8TDV5 3/20 0.36
▸ CREBBP Q92793 1/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ WNT1 P04628 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ HTR4 Q13639 1/20 0.33
▸ CNR1 P21554 1/20 0.32
▸ CYP2C9 P11712 1/20 0.30
▸ CDK9 P50750 1/20 0.30
▸ CETP P11597 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7353205 0.95 GPR119 (0.43) MAOBGPR119CYP3A4CYP2C9
SCHEMBL27498541 0.95 MAOB (0.34) MAOBGPR119CREBBPCYP3A4WNT1
SCHEMBL7350998 0.84 GPR119 (0.39) GPR119CREBBPCYP3A4WNT1GSK3B
SCHEMBL7351896 0.82 GPR119 (0.37) MAOBGPR119CYP3A4CNR1
SCHEMBL7412242 0.82 GPR119 (0.37) MAOBGPR119CYP3A4CNR1
SCHEMBL27497196 0.81 MAOB (0.34) MAOBCREBBPWNT1GSK3BDYRK1A
SCHEMBL7350814 0.81 GPR119 (0.40) GPR119CYP3A4WNT1GSK3BDYRK1A
SCHEMBL7350819 0.81 GPR119 (0.40) GPR119CYP3A4WNT1GSK3BDYRK1A
Trifluoroacetic Acid SCHEMBL7350484 0.80 KHK (0.36) MAOB
Trifluoroacetic Acid SCHEMBL7350478 0.80 KHK (0.36) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0912555-A1 PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS GLAXO GROUP LIMITED (GB) 1999-05-06 — — EP disclosed
WO-1997049699-A1 PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS GLAXO GROUP LIMITED (GB) 1997-12-31 — — WO disclosed
Send feedback